newsfilter
← Latest News
GlobeNewswire·

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL,